Prevalence Study of Depression in Chinese Patients With Type 2 Diabetes (HK13) (DD2)

August 20, 2015 updated by: Juliana Chan, Chinese University of Hong Kong

A Multicentre Study to Investigate the Prevalence and Factors Associated With Depression in Chinese Patients With Type 2 Diabetes

The investigators aim to:

  1. Estimate the prevalence of depression in a consecutive cohort of Chinese patients diagnosed with Type 2 Diabetes (T2D) living in areas of China with different socioeconomical affluence
  2. Examine patients' awareness of the frequent coexistence of these 2 conditions
  3. Analyze the associations between depression and T2D, in particularly the role of metabolic control, socioeconomical status and cognitive-psychological-behavioral factors
  4. To document the predisposing, precipitating and perpetuating factors for depression and their interrelationships in Chinese type 2 diabetic patients

Study Overview

Detailed Description

Overall objectives of this multicentre study are to document;

  1. the prevalence and diagnosis rates of depression in type 2 diabetic (T2D) patients attending 7 centres in 4 major cities in China including Hong Kong (HK), Shanghai (SH), Guangzhou (GZ) and Beijing (BJ)
  2. the predisposing, precipitating and perpetuating factors for depression and their interrelationships in Chinese T2D patients

This study includes two phases. In the phase I pilot study, the investigators shall confirm and compare the validity of Patient Health Questionnaire (PHQ-9) and Clinical Epidemiological Scale for Depression (CESD) in predicting depression in Chinese T2D patients using the SCID as a gold standard. Other questionaires which measure personal and external factors, diabetes associated distress and anxiety, quality of life, mental wellness, self efficacy, health-related behavior and compliance will also be used to document possible predisposing, precipitating and perpetuating factors for depression in diabetes. These results will be used to select a set of tools which are most informative in the evaluation of depression and mental wellness in T2D patients based on their predictions for health behavior, compliance and metabolic control. A random sample of 100 T2D patients will be recruited from 3 Diabetes Centres in GZ, BJ and HK who will complete a full set of questionnaires and structured clinical assessments using a web-based electronic portal. In each of the three centres, all patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of 20 subjects with no or mild symptoms will undergo face-to-face interview by psychiatrists using the following instruments: SCID, BDI, SSI-28 (somatization), Coping (Brief Cope 28, Chinese version).

In Phase II, the investigators shall use a subset of the most informative questionaires to document the rates of depression (diagnosed and undiagnosed) and cognitive-psychological-behavioral factors in a consecutive cohort of Chinese patients with T2D and its associations with metabolic control and psychological behavioral factors. In each of the 7 participating centres in HK, SH, BJ and GZ, 500 consecutive patients will undergo comprehensive clinical assessments for risk factors, complications and medications the JADE (Joint Asia Diabetes Evaluation) e-portal, giving a total of 3500 patients.

This survey which documents the rate of depression in T2D patients using similar methodologies will provide a comprehensive data set for exploratory analysis of the multicausality and heterogeneity of clinical presentation and risk factors in Chinese populations. Once this cohort is established and subject to availability of future funding, they can be followed up prospectively to validate and discover risk factors for new onset of depression. Apart from raising awareness, these data are essential in our design of care models and interventions to tailor the unmet needs of these patients. Data from this study will also provide insights into the effects of rapid acculturation and migration on the double burden of diabetes and depression in Chinese populations.

Study Type

Observational

Enrollment (Actual)

3218

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Beijing, China
        • Peking Union Hospital
      • Beijing, China
        • China-Japan Friendship Hospital
      • Beijing, China
        • 1st Affiliated Hosp, Peking University
      • Bejing, China
        • Peking University People's Hospital
      • Guangzhou, China
        • Third Affiliated Hospital of Sun Yat-sen University
      • Shanghai, China
        • Shanghai Sixth People's Hospital
      • Shatin, Hong Kong
        • YCK Diabetes Assessment Centre, Prince of Wales Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Tertiary Hospitals and community centre

Description

Inclusion Criteria:

  1. Patients diagnosed with type 2 diabetes
  2. Aged ≥25 and <75 years inclusive
  3. Chinese ethnicity

Exclusion Criteria:

  1. Patients with mental/physical handicap and/or difficulty in communication such as deafness, mental retardation
  2. Patients with disabling diseases or reduced life expectancy such as severe heart failure, stroke, respiratory diseases, or late stages of cancer
  3. Patients diagnosed with type 1 diabetes, defined as presentation with diabetic ketoacidosis or unprovoked ketosis or requirement of continuous insulin requirement within 12 months of diagnosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Psychiatrist interview

All patients will receive the same assessments as the 'active comparator' arm, but in addition those patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of subjects with no or mild symptoms will also undergo a face-to-face interview by a trained clinician or psychiatrist using the following instruments:

  • MINI
  • SSI-28 (somatization)

Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:

  • MINI
  • SSI-28 (somatization)
Depression screening

All study participants will undergo a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal.

All patients will also undergo detailed psychological and behavioral assessments using validated questionnaires.

Several specialist questionnaires will also be conducted with all patients, including those on depression, self care and quality of life;

  1. Patient Health Questionnaire (PHQ-9)
  2. Depression Anxiety and Stress Scale (DASS-21)
  3. Diabetes Distress Scale (DDS-17)
  4. Life events questions (Inter-Heart Study)
  5. Diabetes Empowerment Scale (C-DES 20)
  6. Summary of Diabetes Self Care Activities (SDSCA-15)
  7. Euroqol-5D (EQ-5D)

All study participants will undergo;

  1. a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal
  2. a detailed psychological and behavioral assessments using validated questionnaires
  3. several specialist questionnaires on depression, self care and quality of life

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Depression and psychological well-being
Time Frame: 1 year
  1. Depression (PHQ-9, CESD)
  2. Depression Anxiety and Stress Scale (DASS-21)
  3. Diabetes Stress Scale (DSS-17)
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of patients who attain 2 or more of the 'ABC' targets
Time Frame: 1 year

Percentage of patients who attain 2 or more of the following 3 targets:

  1. HbA1c <7%
  2. BP <130/80 mmHg
  3. LDL cholesterol <2.6 mmol/L
1 year
Self care and Efficacy
Time Frame: 1 year
  1. Diabetes Empowerment Scale (C-DES)
  2. Summary of Diabetes Self Care Activities (SDSCA-15)
1 year
Quality of life
Time Frame: 1 year
Using EuroQol-5D (EQ-5D) tool
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Juliana Chan, MD, Chinese University of Hong Kong

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2010

Primary Completion (Actual)

February 1, 2015

Study Completion (Actual)

February 1, 2015

Study Registration Dates

First Submitted

January 14, 2011

First Submitted That Met QC Criteria

January 14, 2011

First Posted (Estimate)

January 17, 2011

Study Record Updates

Last Update Posted (Estimate)

August 24, 2015

Last Update Submitted That Met QC Criteria

August 20, 2015

Last Verified

August 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Psychiatrist Interview

3
Subscribe